Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin
Main Author: | Frontiers Editorial Office |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Oncology |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1337635/full |
Similar Items
-
RETRACTED: Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin
by: Bo Li, et al.
Published: (2021-02-01) -
Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin
by: Frontiers Editorial Office
Published: (2023-12-01) -
Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway
by: Frontiers Editorial Office
Published: (2022-08-01) -
Retraction: Akt inhibition enhanced the growth inhibition effect of low-dose heavy-ion radiation via the PI3K/Akt/P53 signaling pathway in C6 glioblastoma cells
by: Frontiers Editorial Office
Published: (2023-05-01) -
Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer [Retraction]
by: Wang Y, et al.
Published: (2023-09-01)